IL17A and arthritic joint disease: In this model, osteostatin reduced the local production of the pro-inflammatory cytokines IL-1β, IL-6, IL-17, and TNF-α, which are increased in patients with arthritis and enhanced the release of the anti-inflammatory cytokine IL-10.